In the latest quarter, 4 analysts provided ratings for Metagenomi (NASDAQ:MGX), showcasing a mix of bullish and bearish perspectives.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $10.75, a high estimate of $15.00, and a low estimate of $7.00. Surpassing the previous average price target of $9.00, the current average has increased by 19.44%.

Interpreting Analyst Ratings: A Closer Look

The standing of Metagenomi among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Capture valuable insights into Metagenomi's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Metagenomi analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Metagenomi: A Closer Look

Financial Milestones: Metagenomi's Journey

Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.

Negative Revenue Trend: Examining Metagenomi's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -6.87% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Metagenomi's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -163.04%, the company may encounter challenges in effective cost control.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -7.15%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Metagenomi's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.04%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Metagenomi's debt-to-equity ratio is below the industry average. With a ratio of 0.18, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.